Bone turnover, bone loss and fracture risk increase after liver transplantation. It has been postulated that peri-operative administration of a bisphosphonate might prevent bone loss and reduce fracture rate. We studied the effects of a single pre-operative dose of pamidronate on biochemical parameters of skeletal metabolism in the first month after liver transplantation. In a randomized, single-blind study, six of 12 patients with chronic liver disease received 60 mg of pamidronate intravenously on a single occasion 1-30 days before transplantation. Six other patients undergoing transplantation received no pamidronate. We measured serum calcium, phosphate, albumin, bone-specific alkaline phosphatase, plasma parathyroid hormone and tartrate-resistant acid phosphatase before pamidronate infusion and at frequent intervals during the first 30 post-operative days. In treated patients, plasma parathyroid hormone increased 12-fold over baseline values and remained elevated in comparison with baseline at days 26-30 ; serum calcium and phosphate fell significantly, returning to normal at around day 14 postoperatively. There were no significant changes in any parameter in the untreated group. No changes in bone formation or resorption markers were observed in either group. The large increase in plasma parathyroid hormone concentrations in the treated group is probably secondary to the fall in serum calcium. The magnitude of the increase is much greater than that seen after pamidronate infusion in other patient groups. The lack of change in, or correlation of, serum calcium and plasma parathyroid hormone in the untreated group suggests that additional factors release calcium from bone after liver transplantation, presumably by increasing bone resorption.
INTRODUCTION
Patients who have undergone organ transplantation are at increased risk of fragility fractures, with up to 35 % of those undergoing liver transplantation being affected Key words : bisphosphonates, liver transplantation, parathyroid hormone.
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[ [1] [2] [3] [4] . The risk is highest in the first 3 to 6 months postoperatively, consistent with the decreases in bone mineral density of the spine, hip and wrist which have been demonstrated during this period [5, 6] . The pathogenesis of post-transplantation bone loss is understood incom-pletely, but low bone mass before transplantation, treatment with glucocorticoids and other immunosuppressive drugs such as cyclosporin, secondary hyperparathyroidism due to vitamin D deficiency and immobilization may all contribute [7, 8] .
In view of the rapidity of bone loss and high fracture incidence in the early months after transplantation, and the evidence from histomorphometric studies that bone loss is predominantly due to increased bone turnover, peri-operative intervention with an anti-resorptive agent provides a rational approach to prophylaxis. The bisphosphonates are synthetic analogues of pyrophosphate which inhibit bone resorption and reduce bone turnover. They have been used in a wide variety of skeletal disorders including post-menopausal osteoporosis, Paget's disease, malignancy-associated hypercalcaemia and primary hyperparathyroidism [9] [10] [11] [12] . In this randomized controlled study we have investigated the effects of intravenous pamidronate, given pre-operatively, on biochemical indices of skeletal metabolism during the first 30 days after liver transplantation.
METHODS
The patients were recruited into the study at Addenbrooke's Hospital, Cambridge, between May and August 1996. Informed consent was obtained from each patient, the study protocol was approved by the Cambridge Area Health Authority Ethics Committee, and the research was carried out in accordance with the Declaration of Helsinki. The entry criteria were chronic liver failure and cirrhosis necessitating liver transplantation ; patients undergoing re-transplantation were excluded. Patients with renal failure (creatinine clearance 20 ml\min) were also excluded. None of the patients was receiving supplemental vitamin D or calcium. No patient had previously received bisphosphonate therapy. Two patients in the pamidronate-treated group had received hormone replacement therapy for 4 years each. One patient had stopped hormone replacement therapy 5 months before transplantation, and the other was still receiving treatment.
After listing for transplantation, patients received either an infusion of 5 % dextrose with pamidronate, 60 mg, over a period of 6 to 8 h (n l 6) or no treatment, on a randomized basis. The time from listing to transplantation was variable, and ranged from 1-30 days. Investigators were blinded to the randomization.
Blood was drawn before infusion in both groups -this sample provided the baseline data -and at intervals after transplantation. Identical timing of sampling after transplantation was not practicable, but samples were drawn from most patients within each of the following time periods : days 1-3, days 4-7, days 8-10, days 11-15, days 16-20, days 21-25 and days 26-30 post transplantation.
The blood was allowed to stand and clot for 30 min at 4 mC before being spun, and the serum was separated and stored at k70 mC before analysis.
Tartrate-resistant acid phosphatase (TRAP) was measured in plasma EDTA samples as reported by Chamberlain et al. [13] using a sandwich immunoassay. Briefly, microtitre plates were coated with monoclonal antibody 2H1 (2 µg\ml, 100 µl\well) overnight at 4 mC ; the wells were then aspirated and blocked. The wells were washed four times, 50 µl of biotin-5C1 (2 µg\ml) and 50 µl of standards or plasma sample were then added and the wells incubated for 60 min. After washing, Eu-streptavidin (200 ng\ml, 100 µl\well) was added and incubated for 30 min. After the immunoreaction was complete the wells were washed and 200 µl per well of enhancement solution added and after a 5-min incubation the fluorescence was measured. The within-assay coefficient of variation (CV) was 3 % and the betweenassay CV was 7 %.
For the analysis of bone-specific alkaline phosphatase (BSALP) activity, 125 µl of reaction buffer followed by 20 µl of sample or calibrator was added to wells of a microtitre plate coated with an anti-BSALP (mouse) monoclonal antibody. The microtitre plate was covered and incubated at room temperature for 3 h, followed by removal of the contents and washing of the wells with a buffered detergent solution. To each well was then added 150 µl of buffered para-nitrophenol phosphate, pH 10.4, and the contents were incubated at room temperature for 30 min. The reaction was stopped by addition of 100 µl of 1 M sodium hydroxide, and the absorbance read at 405 nm with an automated microtitre plate reader (Molecular Devices, Menlo Park, CA, U.S.A.). The assay was calibrated with the use of BSALP obtained from the SAOS-2 human osteosarcoma cell line, and the results reported in units\l at 37 mC (conversion from results at 25 mC was established in a separate experiment). The reagents were supplied by Metra Biosystems (Mountain View, CA, U.S.A.).
Plasma parathyroid hormone (PTH) was measured using the Immulite Intact PTH method, a solid-phase two-site chemiluminescent immunometric assay. The assay was supplied as a solid phase, a polystyrene bead enclosed within an Immulite test unit, coated with an affinity-purified goat polyclonal anti-PTH (44-84) antibody, to which was added 50 µl of serum, and an alkalinephosphatase-conjugated affinity-purified goat polyclonal anti-PTH (1-34) antibody. These were incubated together for 60 min at 37 mC within the Immulite test unit with intermittent agitation. During this time, intact PTH in the sample was bound to form an antibody sandwich complex. Unbound conjugate was removed by a centrifugal wash, after which the chemiluminescent substrate [4-methoxy-4-(3-phosphatephenyl)-spiro-(1,2-dioxetane-3,2h-adamantane] was added, and the test unit incubated for a further 10 min. The photon output was proportional to the concentration of intact PTH in the sample. The within-assay CV was 4 % and the betweenassay CV was 8 %.
Calcium, phosphate and albumin were measured by colorimetric methods (within-and between-assay CVs 1-2 % in each case) using an autoanalyser, and the values of serum calcium presented have been corrected for serum albumin concentrations.
Statistical analyses were undertaken using Data Desk 5.0.1 for the Macintosh. Data were log-transformed to adjust for positive skew where appropriate before t-test or F-test. Multiple regression analysis was used to test the independent effects of some variables on changes in serum and plasma markers. The small numbers of patients in each study group preclude the detection of subtle changes ; this study was not designed to assess clinical outcome but only to document acute changes in parameters of skeletal metabolism.
RESULTS
Pre-operatively there was no significant difference between the groups in any of the parameters assessed. The patients' details are shown in Table 1 .
Plasma PTH
The most significant change observed was in the plasma concentration of PTH. The magnitude of the increases above baseline in mean plasma PTH was 12-fold at days 4-7 in the treated group and 2-fold at days 1-3 in the untreated group. The time course of the change in PTH after transplantation is shown in Figure 1 for the two groups.
The concentration of PTH increased in both groups in the first 3-day period after transplantation, without a significant difference between the groups. Plasma PTH in one patient treated with pamidronate 4 days before transplantation reached an extremely high value of 1190 pg\ml, causing a large positive skew in the data for days 1-3 in the treated group. In the remaining treated patients, the maximal increase in plasma PTH was observed in the days 4-7 period.
Within the treatment group, F-testing for the comparison of multiple means indicated that one or more means were different (P 0.0001). t-tests of the individual group means versus the baseline mean showed significant differences at all time points, indicating that plasma PTH had still not returned to pretreatment concentrations by day 30 post transplant. Within the control group, F-testing showed no individual mean as being significantly different (P l 0.24).
Comparing the two groups, there were significant differences at days 4-7, days 8-10, days 16-20 and days 21-25 ( Figure 1 ). There was no relationship between peak plasma PTH and the time from pamidronate infusion to liver transplantation.
Serum calcium
Serum calcium (corrected for albumin) remained unchanged in the control group, but fell progressively in the group pretreated with pamidronate, reaching a nadir during the days 4-7 period (F-test of multiple means :
Figure 3 Serum phosphate concentrations before transplantation and at intervals after transplantation in patients pretreated with pamidronate (upper panel) and controls
The data are shown as box plots, with the central bar corresponding to the median and the upper and lower sides of the box the 25th and 75th centiles of the data. Outliers more than 2 S.D.s from the median are shown as circles, and extreme outliers more than 4 S.D.s from the median as stars. a, P 0.05 compared with control. P l 0.005) and returning to baseline after 2 weeks ( Figure  2) . The difference between the two groups did not reach statistical significance however.
Serum phosphate
Serum phosphate did not vary significantly in the untreated group (Figure 3 ). In the treated group, the fall in serum phosphate was significant (F-test of multiple means : P l 0.04), and values differed significantly between the groups at days 1-3 and days 4-7 (P l 0.03 for both).
Parameters of formation and resorption
With regard to the measurements of BSALP and TRAP, there were no statistically significant differences within or between groups at any time point after transplantation (Table 2) . BSALP was slightly higher in the treatment group before infusion (46 versus 30 units\l), but there was no change from day 1-3 onwards in BSALP concentration in either group.
There were no effects of age, sex or cause of liver failure on any of the parameters measured. Pamidronate in liver transplantation 
Relationship of plasma PTH and serum calcium
The relationships between serum calcium and plasma PTH are shown in Figure 4 . There was a strong correlation between the two variables in the group treated with pamidronate (r# l 0.33, P 0.001), but not in the untreated group.
DISCUSSION
Our results demonstrate highly significant effects of preoperative pamidronate infusion on biochemical indices of skeletal metabolism in patients undergoing liver transplantation. Plasma PTH rose to 12 times the baseline value, whereas serum calcium and phosphate fell, returning to normal 2 weeks post transplant. In contrast, in those patients who had not received pamidronate, there were no statistically significant changes. There was a nonsignificant increase in plasma PTH at days 26-30 in the untreated group, consistent with our previous observations in a larger group of patients (n l 27) undergoing liver transplantation of increased plasma PTH 1 and 2 months post-operatively [8] .
For logistic reasons, the time between pamidronate infusion and transplantation varied from 1 to 30 days. However, the observed increases in plasma PTH concentrations could not be explained as a direct effect of the previously administered pamidronate, since five of six treated patients showed a higher concentration of plasma PTH at days 4-7 than at days 1-3. If the increase in circulating PTH post-operatively were simply a reflection of an increase pre-operatively, successive values in the treated patients would be declining.
Body et al. [14] demonstrated a 3-fold increase in serum PTH levels, maximal on day 7, and a similar time course and magnitude of change in serum calcium, in patients treated for tumour-induced osteolysis with a single pamidronate infusion. Other studies have generally reported similar increases in other patient groups receiving bisphosphonates [15, 16] . In the present study, the serum PTH concentration increased almost 30-fold over baseline in one patient (contemporaneous serum calcium 2.02 mmol\l, the lowest value recorded in the treated group), whereas the mean change in the group was 12-fold over baseline. The magnitude of increase in plasma PTH levels in pamidronate-treated patients was considerably greater than that reported in other patient groups. The prolonged fall in serum calcium in the face of substantially elevated plasma PTH suggests that bone, one of the two principal PTH targets, is not being resorbed in treated patients. It is not yet clear how the need for calcium arises ; influx into damaged or compromised graft or host tissues is likely to engender the greatest requirement, and urinary losses due to steroid administration might also contribute.
The relationship between serum calcium and plasma PTH in treated patients was highly significant, in contrast to the untreated group. This implies that although additional factors may contribute to the release of calcium after liver transplantation, PTH remains the principal homoeostatic mechanism for serum calcium. Multiple cytokines are released immediately after graft reperfusion, which could influence bone metabolism [17, 18] . Interleukins 1 and 6 (IL-1, IL-6) and tumour necrosis factor-α (TNF-α) rapidly appear in the graft's venous effluent after engraftment ; TNF-α may act as a graft survival factor [19] . IL-1 is the most potent known stimulus to bone resorption [20] , and may act both immediately and over the longer term through its effects on multinucleated giant cell formation [21] . IL-6 regulates osteoclast development, and stimulates bone resorption in co-operation with IL-1 in vivo [22] . TNF-α can increase the number of osteoclasts and may also regulate the differentiation of osteoclasts [23] . These cytokines may therefore contribute to the release of calcium from bone after transplantation. In addition, cyclosporin, administered both intra-and postoperatively might be expected to increase bone resorption in this setting, as it does in others [24] . It is quite possible that these factors would be sufficient, in combination with relatively modest amounts of PTH, to maintain normocalcaemia in the face of increased demand post transplant. Immobilization is unlikely to contribute significantly to bone loss since patients are mobilized in the first 2 to 3 days after transplantation.
The bone loss, high fracture incidence and histomorphometric evidence of increased bone turnover, which have all been reported during the first few months after liver transplantation, support the contention that early in the post-operative period there is a significant increase in bone resorption. Despite this, no significant changes in the serum BSALP and plasma TRAP, markers of bone formation and resorption respectively, were demonstrated. This may reflect their limitations as biochemical markers rather than the absence of an increase in bone turnover, since there is cross-reactivity between bone and liver isoenzymes of alkaline phosphatase in patients with liver disease and plasma TRAP concentrations may not be a sensitive index of bone resorption [25] . In addition, changes of up to 1.5 times the standard deviation of each measurement may have been missed due to the small sample size.
There is evidence from histomorphometric studies that bone turnover is generally normal or reduced in patients with chronic liver disease before transplantation, and that bone loss early after transplantation is predominantly due to increased bone turnover [26] . The results of the present study suggest that bone resorption can be effectively prevented in this vulnerable group of patients by the administration of pamidronate as much as 30 days before transplantation. Further studies are required to establish definitively a protective effect of such treatment against fracture.
